Literature DB >> 6391147

Immunoreactive secretory component of IgA in human tissues and tumors.

J J Brooks, C S Ernst.   

Abstract

Secretory component (SC) of IgA is known to be produced by many glandular epithelial cells. To assess the usefulness of this antigen as a glandular tumor differentiation marker, the authors evaluated its normal body distribution and tested a variety of glandular neoplasms. The known normal distribution of SC was confirmed and extended to include the prostate. Immunoreactive SC was detected only in epithelial and glandular tumors. Many types of well-differentiated adenocarcinomas, (ovary, prostate, small bowel, pancreas, stomach, biliary) however, contained little or no immunoreactive SC. Therefore, the authors conclude that immunoreactive SC cannot be used as a general differentiation marker in tumors of glandular derivation. A high frequency of antigenic expression was found in adenocarcinomas of the lung (4/10), breast (5/10), and colon (24/27). No correlation between expression and tumor differentiation was observed in pulmonary or mammary tumors. Only in colonic neoplasia was such a relationship detected. SC expression in colonic tumors was not related to mucin content but was associated with the presence of a visible brush border.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391147     DOI: 10.1093/ajcp/82.6.660

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Declining immunoglobulin A production in prostates of men with AIDS.

Authors:  H J Carson; N E Lueck
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Total IgA and IgG in Sera of Patients With Different Primary Malignancies.

Authors:  Terezija M Hrzenjak; Ante Roguljic; Palma Efenberger-Marinculic; Maja Popovic; Zoran Pisl
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

3.  Secretory component in differentiating normal epithelium, benign lesions and malignancy in the human breast as monitored by monoclonal antibodies.

Authors:  J Bártek; H Tlaskalová-Hogenová; Z Stasková; J Simecková; B Vojtĕsek; A Rejthar; J Kovarík; J Bartková
Journal:  Histochemistry       Date:  1989

4.  Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma.

Authors:  M Rossel; C Billerey; H Bittard; P Ksiazek; D Alber; J P Revillard; D A Vuitton
Journal:  Urol Res       Date:  1991

5.  Immunohistochemical markers in the identification of metastatic breast cancer.

Authors:  P C de Almeida; C B Pestana
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

6.  Circulating secretory component in relation to early diagnosis and treatment of liver metastasis from colorectal carcinomas.

Authors:  D Kvale; J Norstein; G I Meling; O P Børmer; P Brandtzaeg; F Langmark; T O Rognum
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

7.  Early detection of liver metastasis in patients with colorectal carcinoma by increased levels of circulating IgA- and IgM-associated secretory component.

Authors:  D Kvale; T O Rognum; P Brandtzaeg
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.